Tennekes H A, Edler L, Kunz H W
Carcinogenesis. 1982;3(8):941-5. doi: 10.1093/carcin/3.8.941.
The current study was undertaken to investigate the dose-response characteristics of dieldrin-mediated enhancement of liver tumour formation in CF-1 mice. The median time to tumour development was established in controls, and in dieldrin-treated animals at six levels of continuous exposure (0.1, 1, 2.5, 5, 10 and 20 p.p.m.). The results of the analysis, which was based on liver tumour data from two parallel chronic feeding studies involving 1800 mice, are at variance with those reported by Druckrey for various established chemical carcinogens. In a double-logarithmic system of coordinates there was no linear relationship between the median total dose or the median time to tumour formation and the daily dieldrin exposure level. These results suggest that the tumourigenicity of this compound in CF-1 mouse liver is determined not by the sum of all consecutive doses, but rather by the level of daily exposure, and, presumably, the duration of treatment. This concept is consistent with the observed dose-dependency and reversible nature of dieldrin-induced subcellular changes in mouse liver. These considerations, together with evidence that dieldrin and its mammalian metabolites possess neither genotoxic activity nor potential, are not inconsistent with the concept that this compound is devoid of initiating potential, and operates by enhancing the effect of a genetically linked oncogenic factor in CF-1 mouse liver.
本研究旨在调查狄氏剂介导的CF-1小鼠肝脏肿瘤形成增强的剂量反应特征。在对照组以及连续暴露于六个剂量水平(0.1、1、2.5、5、10和20 ppm)狄氏剂的动物中确定了肿瘤发生的中位时间。该分析结果基于两项涉及1800只小鼠的平行慢性喂养研究的肝脏肿瘤数据,与Druckrey报道的各种已确定化学致癌物的结果不同。在双对数坐标系统中,中位总剂量或肿瘤形成的中位时间与每日狄氏剂暴露水平之间没有线性关系。这些结果表明,该化合物在CF-1小鼠肝脏中的致瘤性不是由所有连续剂量的总和决定的,而是由每日暴露水平以及可能的治疗持续时间决定的。这一概念与狄氏剂诱导的小鼠肝脏亚细胞变化的剂量依赖性和可逆性一致。这些考虑因素,再加上狄氏剂及其哺乳动物代谢产物既不具有遗传毒性活性也不具有潜在遗传毒性的证据,与该化合物缺乏启动潜力并通过增强CF-1小鼠肝脏中与基因相关的致癌因子的作用发挥作用的概念并不矛盾。